Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04446351 | Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors | PHASE1 | ACTIVE NOT_RECRUITING | 107 | — | — | Jun 25, 2020 | Dec 31, 2026 | Oct 27, 2025 | 11 | United States, Canada +2 |
| Arm | Type | Description |
|---|---|---|
| Participants receiving GSK6097608 monotherapy (Arm A) | EXPERIMENTAL | Participants will be administered an intravenous (IV) infusion of GSK6097608 every 3 weeks as monotherapy in escalating doses. |
| Participants receiving GSK6097608 plus dostarlimab (Arm B) | EXPERIMENTAL | Participants will be administered IV infusion of GSK6097608 every 3 weeks in escalating doses followed by dostarlimab. |
| Participants receiving dostarlimab monotherapy (Arm D) | EXPERIMENTAL | Participants will be administered an IV infusion of dostarlimab monotherapy (1 cohort will receive dostarlimab every 3 weeks and 1 cohort will receive dostarlimab every 6 weeks). |
| Participants receiving dostarlimab plus belrestotug (Arm E) | EXPERIMENTAL | Participants will be administered IV infusions of dostarlimab followed by belrestotug, every 3 weeks. |
| Participants receiving dostarlimab plus belrestotug plus GSK6097608 (Arm F) | EXPERIMENTAL | Participants will be administered an IV infusion of dostarlimab followed by belrestotug followed by GSK6097608 every 3 weeks. |
| Participants receiving dostarlimab plus cobolimab (Arm G) | EXPERIMENTAL | Participants will be administered an IV infusion of cobolimab followed by dostarlimab |
| Name | Type | Description |
|---|---|---|
| GSK6097608 | DRUG | GSK6097608 will be administered as an IV infusion. |
| Dostarlimab | DRUG | Dostarlimab will be administered as an IV infusion. |
| Cobolimab | DRUG | Cobolimab will be administered as an IV infusion. |
| Belrestotug | DRUG | Belrestotug will be administered as an IV infusion. |
Inclusion Criteria: * Adults 18 years of age or older (or \>=20 years of age in Arm-A Japan, Arm-D Japan, Arm E-Japan, Arm F-Japan, and Arm G-Japan) * Female participants of childbearing potential must agree to use a highly effective form of contraception * Histological or cytological documentation...